Jazz Pharmaceuticals vs BeOne Medicines
JAZZ and ONC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JAZZ and ONC compare
BeOne Medicines is the larger company, worth 39 times as much as Jazz Pharmaceuticals ($616B against $15.7B).
On earnings, Jazz Pharmaceuticals is cheaper: it trades at 78.7× trailing earnings, against 694× for BeOne Medicines.
BeOne Medicines grew revenue faster over the last twelve months (32.9% versus 13.5% for Jazz Pharmaceuticals).
BeOne Medicines keeps more of each dollar of sales as profit, with a net margin of 13.9% compared with 4.4% at Jazz Pharmaceuticals.
BeOne Medicines scores higher on the StockData Score (14 against 7 for Jazz Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JAZZ | ONC |
|---|---|---|
| Size and price | ||
| Market cap | $15.7B | $616B |
| Share price | $241.55 | $416.54 |
| Change, 1 year | 76.7% | 10.4% |
| Change, 5 years | 88.2% | 14.3% |
| Beta (5Y) | 0.53 | 1.05 |
| Employees | 2,890 | 12K |
| StockData Score | ||
| Total score | 7 | 14 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 4 (better) |
| Performance score | 3 | 4 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 78.7× (better) | 694× |
| P/S | 3.3× (better) | 93.2× |
| P/B | 3.7× (better) | 106× |
| EV/EBITDA | 43.2× (better) | 450× |
| P/FCF | 9.7× (better) | 425× |
| FCF yield | 10.3% (better) | 0.24% |
| Fair value | $110.08 | $20.47 |
| Margin of safety | −119% (better) | −1935% |
| Growth | ||
| Revenue growth (TTM) | 13.5% | 32.9% (better) |
| Revenue growth, 5Y average | 12.5% | 76.8% (better) |
| Net income growth (TTM) | – | 1236% |
| EPS growth (TTM) | – | 1900% |
| Profitability | ||
| Gross margin | – | 89.4% |
| Operating margin | 9.0% | 17.8% (better) |
| Net margin | 4.4% | 13.9% (better) |
| FCF margin | 34.4% (better) | 21.9% |
| Return on equity | 5.1% | 18.4% (better) |
| Return on invested capital | 4.5% | 88.9% (better) |
| Financial health | ||
| Debt / equity | 1.33 | 0.21 (better) |
| Net debt / EBITDA | 6.37 (better) | −3.37 |
| Interest coverage | – | 8.3× |
| Current ratio | 1.82 | 3.55 (better) |
| Altman Z-score | 1.97 | 91.79 (better) |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 99.2% | 2.4% |
| Held by insiders | 3.4% | 14.2% |
| Insider net buying, 12 months | −$67.1M (better) | −$384M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 9.3% | – |
Go deeper
- JAZZ stock overview
- JAZZ income statement
- JAZZ valuation and score
- ONC stock overview
- ONC income statement
- ONC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.